Eisai's Halaven shows survival benefit in metastatic soft tissue sarcoma in new study

1 August 2016

Japanese pharma major Eisai (TYO: 4523) has announced the results of a new Phase III study of its in-house discovered and developed oncology agent Halaven (eribulin mesylate) in patients with locally-advanced, recurrent or metastatic soft tissue sarcoma.

Study 309 was a Phase III clinical trial which examined the efficacy and safety of eribulin versus dacarbazine in 452 adults with locally-advanced, recurrent or metastatic soft tissue sarcoma, liposarcoma or leiomyosarcoma, who had disease progression following standard therapies.

According to the results of pre-planned sub-group analyses of the duration of response in patients with liposarcoma and leiomyosarcoma, median duration of response for the eribulin treatment was 12.5 months, and for dacarbazine it was 4.2 months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK